Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena Buckstein

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Annals of Hematology|October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registryBrett L Houston, Jennifer Jayakar, Richard A Wells, et al.
British Journal of Haematology|March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective studyRena Buckstein, Richard A Wells, Nancy Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.
Plos One|March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic reviewYaping Chang, Gordon H Guyatt, Trevor Teich, et al.
Blood Cancer Journal|December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDSRami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Nature Communications|May 22, 2026
Initial leukemic epigenomic state determines hypomethylating agent responseAparna Gopal, Derek Tam, Franziska Mey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Blood|July 7, 2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblastsAmer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
British Journal of Haematology|June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyIrina Amitai, Michelle Geddes, Nancy Zhu, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Annals of Hematology|October 5, 2017
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registryBrett L Houston, Jennifer Jayakar, Richard A Wells, et al.
British Journal of Haematology|March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective studyRena Buckstein, Richard A Wells, Nancy Zhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS StudyLaurie H Sehn, Andre Goy, Fritz C Offner, et al.
Plos One|March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic reviewYaping Chang, Gordon H Guyatt, Trevor Teich, et al.
Blood Cancer Journal|December 31, 2025
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDSRami S Komrokji, Valeria Santini, Amer M Zeidan, et al.
Nature Communications|May 22, 2026
Initial leukemic epigenomic state determines hypomethylating agent responseAparna Gopal, Derek Tam, Franziska Mey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Blood|July 7, 2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblastsAmer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
British Journal of Haematology|June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyIrina Amitai, Michelle Geddes, Nancy Zhu, et al.
Blood Advances|August 8, 2020
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Gordon Guyatt, Gregory Abel, et al.
Pageof 14